New All-Oral Combination Therapy for CLL Shows Impressive Results

A new study using a combination of the 2 oral drugs, Copiktra and Venclexta, showed promising results for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
February 2020 Vol 6 No 1
Dana Taylor

A study investigating the combination of 2 oral drugs—Copiktra (duvelisib) and Venclexta (venetoclax)—showed promising results in patients with relapsed (coming back) or refractory (not responding to treatment) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The results were presented at the American Society of Hematology meeting in December 2019.

Jennifer L. Crombie, MD

Each of these drugs is approved to be used alone in patients with CLL, “but this is the first time these agents are being combined,” said Jennifer L. Crombie, MD, Medical Oncologist, Dana-Farber Cancer Institute in Boston, who discussed the results. “We’re excited about the potentially being an all-oral and possibly time-limited treatment option,” said Dr. Crombie.

Of 12 patients who received treatment with this combination in the early phase of the study, 11 (92%) patients had a response, including 4 (33%) patients who had a complete response or complete response with incomplete hematologic recovery.

“With some treatments, even novel agents, patients often require indefinite therapy,” according to Dr. Crombie. For patients with high-risk biologic abnormalities, such as P53 mutations or deletion 17p, or patients whose disease progressed after receiving treatment with a Bruton tyrosine kinase inhibitor, the duration of response to treatment with a single drug is often short, so there is a need to try a combination of more than 1 drug, she said.

“This was a high-risk patient population,” said Dr. Crombie, meaning many of them had the biologic abnormalities that make treatment more complicated.

In this study, patients received treatment with Copiktra first, then Venclexta was added, for a treatment of 1 year. If after 1 year the patients had undetectable minimal residual disease, they had the option of discontinuing therapy.

Overall, 4 (33%) patients had undetectable minimal residual disease in the blood, and 4 (33%) had undetectable minimal residual disease in the marrow.

This combination was generally well-tolerated, and there was no evidence of tumor lysis syndrome. Serious side effects included elevation in amylase and/or lipase, 1 case of febrile neutropenia, and 1 case of pneumonia.

Share this:

Recommended For You
CLL Monthly MinutesLeukemia
Acalabrutinib versus Ibrutinib in Previously Treated CLL
The first head-to-head trial of these drugs shows comparable efficacy with a better cardiovascular safety profile for acalabrutinib.
CLL Monthly MinutesLeukemia
Protecting Patients with CLL from COVID-19
A recent study provides some of the first data on COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
CLL Monthly MinutesLeukemia
Promising Data on Zanubrutinib in Previously Treated CLL
Preliminary results from the ongoing ALPINE study suggest that zanubrutinib may have superior efficacy and an improved safety profile compared with ibrutinib in previously treated patients with chronic lymphocytic leukemia.
CLL Monthly MinutesLeukemia
Acalabrutinib Shows Superior Efficacy Over Chemoimmunotherapy
Results from the 4-year follow-up of the ELEVATE-TN study support acalabrutinib with or without immunotherapy in previously untreated patients with chronic lymphocytic leukemia.
Last modified: April 7, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest